John R. Johnson

发表

Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma

K. He, R. Pazdur, R. Justice, 2007, Clinical Cancer Research.

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

R. Pazdur, J. Gobburu, M. Rothmann, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

R. Pazdur, R. Justice, R. Sridhara, 2008, The oncologist.

Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.

R. Pazdur, R. Justice, Martin H. Cohen, 2011, The oncologist.

Letrozole in the Extended Adjuvant Treatment of Postmenopausal Women with History of Early-Stage Breast Cancer Who Have Completed 5 Years of Adjuvant Tamoxifen

R. Pazdur, R. Sridhara, B. Mann, 2005, Clinical Cancer Research.

U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.

R. Pazdur, Martin H. Cohen, John R. Johnson, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA drug approval summary: erlotinib (Tarceva) tablets.

R. Pazdur, R. Sridhara, Martin H. Cohen, 2005, The oncologist.

The Role of SN‐38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity

M. Ratain, J. Gobburu, F. Innocenti, 2007, Journal of clinical pharmacology.

Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

R. Pazdur, Martin H. Cohen, John R. Johnson, 2005, Clinical Cancer Research.

Report from the Food and Drug Administration Pemetrexed in Malignant Pleural Mesothelioma

Robert M. White, R. Pazdur, J. Gobburu, 2005 .

Pemetrexed in malignant pleural mesothelioma.

Robert M. White, R. Pazdur, J. Gobburu, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Accelerated approval of oncology products: the food and drug administration experience.

P. Keegan, R. Pazdur, R. Justice, 2011, Journal of the National Cancer Institute.

FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.

R. Pazdur, R. Sridhara, Martin H. Cohen, 2005, The oncologist.

Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.

R. Pazdur, Martin H. Cohen, Gang Chen, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.

R. Pazdur, R. Justice, Martin H. Cohen, 2008, The oncologist.

US Food and Drug Administration approval overview in metastatic breast cancer.

P. Keegan, R. Pazdur, P. Cortazar, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report from the FDA Approval Summary: Letrozole in the Treatment of Postmenopausal Women with Advanced Breast Cancer

R. Pazdur, Martin H. Cohen, Gang Chen, 2002 .

Report from the FDA Approval Summary: Imatinib Mesylate Capsules for Treatment of Adult Patients with Newly Diagnosed Philadelphia Chromosome- positive Chronic Myelogenous Leukemia in Chronic Phase

R. Pazdur, J. Gobburu, M. Rothmann, 2003 .

Approval Summary: Nelarabine for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma

R. Pazdur, J. Gobburu, R. Justice, 2006, Clinical Cancer Research.

Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen

P. Zimmerman, R. Pazdur, J. Gobburu, 2005, Clinical Cancer Research.

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Richard Pazdur, Robert Justice, R. Pazdur, 2007, The oncologist.

FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation

Justin C. Earp, Amy McKee, R. Pazdur, 2014, Clinical Cancer Research.

End points and United States Food and Drug Administration approval of oncology drugs.

Richard Pazdur, R. Pazdur, Grant A. Williams, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.

R. Pazdur, R. Justice, Martin H. Cohen, 2012, The oncologist.

FDA drug approval summaries: pemetrexed (Alimta).

Richard Pazdur, R. Pazdur, John R. Johnson, 2004, The oncologist.

Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.

P. Keegan, R. Pazdur, R. Justice, 2010, Journal of the National Cancer Institute.

Accelerated approval of oncology products: a decade of experience.

Richard Pazdur, P. Keegan, R. Pazdur, 2004, Journal of the National Cancer Institute.

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).

R. Pazdur, R. Justice, R. Sridhara, 2010, The oncologist.

Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

Mark Rothmann, Richard Pazdur, Martin Cohen, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

End P oints a nd U nited S tates F ood a nd D rug A dministration Approval o f O ncology D rugs

R. Pazdur, Grant A. Williams, John R. Johnson, 2003 .

Accelerated approval and oncology drug development timelines.

Richard Pazdur, Robert Justice, Rajeshwari Sridhara, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.

S. Hirschfeld, R. Pazdur, Martin H. Cohen, 2001, The oncologist.

Metastatic breast cancer (MBC): FDA approval overview

R. Pazdur, P. Cortazar, R. Justice, 2008 .

Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials.

R. Wittes, J. Woodcock, R. Temple, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.

P. Zimmerman, R. Pazdur, A. Senderowicz, 2007, Oncology.

U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.

R. Pazdur, John R. Johnson, M. Cohen, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.